CVS Health lifts full-year guidance during investor event

CVS Health raised its full-year 2025 targets at Investor Day, boosting revenue guidance to at least $400.0 billion (from $397.3B), adjusted EPS to $6.60–$6.70 (from $6.55–$6.65), adjusted operating income to $14.22B–$14.39B and GAAP operating income to $4.37B–$4.54B, while maintaining cash flow from operations at $7.5B–$8B. The company also issued initial 2026 targets—revenue of at least $400B, adjusted EPS $7.00–$7.20 and operating cash flow of at least $10B—and reaffirmed a mid‑teens adjusted EPS CAGR through 2028 driven by Aetna, CVS Caremark and its health‑care delivery operations; shares jumped about 3% to roughly $79 on the update.

Analysis

CVS Health raised its full-year 2025 guidance at Investor Day, increasing revenue guidance to at least $400.0 billion from $397.3 billion and adjusted EPS to $6.60–$6.70 (prior $6.55–$6.65); adjusted operating income was nudged to $14.22B–$14.39B (from $14.14B–$14.31B) and GAAP operating income to $4.37B–$4.54B (from $4.29B–$4.46B), while cash flow from operations was maintained at $7.5B–$8.0B; shares rose about 3% to roughly $79 on the update.

The company provided initial 2026 targets of at least $400B revenue, adjusted EPS of $7.00–$7.20 and operating cash flow of at least $10B, and reiterated a mid‑teens adjusted EPS CAGR through 2028 driven by Aetna, CVS Caremark and health‑care delivery operations, signaling management confidence in ongoing integration and margin improvement.

The revisions are incremental but directionally positive: they reflect improving profitability and a material step-up in targeted operating cash flow for 2026, which could support deleveraging or capital allocation options if achieved. Key execution risk remains realizing the $10B cash‑flow target and sustaining mid‑teens EPS growth; investors should monitor upcoming quarterly results for revenue mix, margin trends and cash‑flow progress to validate the guidance trajectory.

Key Decisions for Investors

• Consider increasing exposure modestly in line with the upgraded guidance, given the raised EPS and revenue targets and the 2026 operating cash flow objective
• Monitor quarterly beats on revenue, margins and operating cash flow and be prepared to reassess if the company misses early indicators versus the $10B 2026 cash‑flow or EPS ramp
• If the stock extends well beyond the initial ~3% move without supporting operational beats, consider trimming or hedging to lock profits while retaining exposure to execution upside